AzurRx BioPharma, Inc. (AZRX) Stock

About AzurRx BioPharma, Inc.

AzurRx BioPharma, Inc., a Brooklyn, New York-based company employing 12 full-time individuals, focuses on the discovery and advancement of non-systemic biological treatments for various gastrointestinal conditions. Its current developmental portfolio comprises two therapeutic protein assets: MS1819 and AZX1101. MS1819 is an acid-stable lipase enzyme (LIP2), originating from Yarrowia lipolytica, which AzurRx is genetically engineering to address exocrine pancreatic insufficiency (EPI). EPI is a debilitating disorder often seen in patients with chronic pancreatitis (CP) and cystic fibrosis (CF). The second promising compound, AZX1101, is a recombinant beta-lactamase combination sourced from bacteria. This asset is being engineered with a dual aim: to avert nosocomial infections caused by resistant bacterial strains, especially after intravenous beta-lactam antibiotic administration, and to mitigate antibiotic-associated diarrhea (AAD).

AzurRx BioPharma, Inc. is headquartered in US.

AzurRx BioPharma, Inc. (AZRX) stock trades at $3.45 with a market capitalization of $3.43M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.73, reflecting a net loss over the last twelve months, price-to-book of 0.65, price-to-sales of 46.10. Over the past 52 weeks the stock has ranged between $2.68 and $26.30, and currently trades 86.9% below its 52-week high.

On profitability, AzurRx BioPharma, Inc. generates a return on equity (ROE) of -49.81% (negative, reflecting a net loss), return on capital employed of -31.12%.

Official website: enterothera.com